CIN-108

CIN-108 is a small molecule inhibiting defective in cullin neddylation 1 (DCN1) from binding in the pocket where is it necessary to promote neddylation and interfere with the progression of multiple solid tumors.

Pre-clinical

CIN-108
OVERVIEW:

CinSano’s CIN-108, a small molecule compound that inhibits a novel, well-studied oncogene target, DCN1, which is amplified in multiple cancer types and correlates with more severe prognosis. Licensed in 2021 by CinRx, the goal for CIN-108 is to disrupt the neddylation pathway by preventing binding of DCN1 to the pocket necessary for it to promote neddylation. The CIN-108 compound series is currently being optimized. Regulatory and human clinical development milestones are planned for 2023.

Solid Tumor
Metrics:

Represent approximatively 90% of adult human cancers

Sources:

American Cancer Society

REASONS
TO BELIEVE

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES